Literature DB >> 24781136

Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10.

Bin Yang1, Shaoyong Li2, Hongyan Wang3, Yansu Guo4, Dominic J Gessler5, Chunyan Cao6, Qin Su7, Joshua Kramer8, Li Zhong9, Seemin Seher Ahmed2, Hongwei Zhang10, Ran He7, Ronald C Desrosiers8, Robert Brown11, Zuoshang Xu12, Guangping Gao13.   

Abstract

Some recombinant adeno-associated viruses (rAAVs) can cross the neonatal blood-brain barrier (BBB) and efficiently transduce cells of the central nervous system (CNS). However, in the adult CNS, transduction levels by systemically delivered rAAVs are significantly reduced, limiting their potential for CNS gene therapy. Here, we characterized 12 different rAAVEGFPs in the adult mouse CNS following intravenous delivery. We show that the capability of crossing the adult BBB and achieving widespread CNS transduction is a common character of AAV serotypes tested. Of note, rAAVrh.8 is the leading vector for robust global transduction of glial and neuronal cell types in regions of clinical importance such as cortex, caudate-putamen, hippocampus, corpus callosum, and substantia nigra. It also displays reduced peripheral tissue tropism compared to other leading vectors. Additionally, we evaluated rAAVrh.10 with and without microRNA (miRNA)-regulated expressional detargeting from peripheral tissues for systemic gene delivery to the CNS in marmosets. Our results indicate that rAAVrh.8, along with rh.10 and 9, hold the best promise for developing novel therapeutic strategies to treat neurological diseases in the adult patient population. Additionally, systemically delivered rAAVrh.10 can transduce the CNS efficiently, and its transgene expression can be limited in the periphery by endogenous miRNAs in adult marmosets.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24781136      PMCID: PMC4089005          DOI: 10.1038/mt.2014.68

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  49 in total

Review 1.  Alzheimer's disease.

Authors:  Jeffrey L Cummings
Journal:  N Engl J Med       Date:  2004-07-01       Impact factor: 91.245

2.  AAV transcytosis through barrier epithelia and endothelium.

Authors:  Giovanni Di Pasquale; John A Chiorini
Journal:  Mol Ther       Date:  2005-12-20       Impact factor: 11.454

3.  Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain.

Authors:  Cassia N Cearley; John H Wolfe
Journal:  Mol Ther       Date:  2006-01-18       Impact factor: 11.454

4.  Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

Authors:  Roberto Calcedo; Luk H Vandenberghe; Guangping Gao; Jianping Lin; James M Wilson
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

5.  microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors.

Authors:  A Geisler; A Jungmann; J Kurreck; W Poller; H A Katus; R Vetter; H Fechner; O J Müller
Journal:  Gene Ther       Date:  2010-11-04       Impact factor: 5.250

6.  Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer.

Authors:  Albert Ruzo; Sara Marcó; Miquel García; Pilar Villacampa; Albert Ribera; Eduard Ayuso; Lucca Maggioni; Federico Mingozzi; Virginia Haurigot; Fatima Bosch
Journal:  Hum Gene Ther       Date:  2012-10-17       Impact factor: 5.695

7.  A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice.

Authors:  Seemin Seher Ahmed; Huapeng Li; Chunyan Cao; Elif M Sikoglu; Andrew R Denninger; Qin Su; Samuel Eaton; Ana A Liso Navarro; Jun Xie; Sylvia Szucs; Hongwei Zhang; Constance Moore; Daniel A Kirschner; Thomas N Seyfried; Terence R Flotte; Reuben Matalon; Guangping Gao
Journal:  Mol Ther       Date:  2013-07-02       Impact factor: 11.454

8.  Alzheimer disease in the US population: prevalence estimates using the 2000 census.

Authors:  Liesi E Hebert; Paul A Scherr; Julia L Bienias; David A Bennett; Denis A Evans
Journal:  Arch Neurol       Date:  2003-08

Review 9.  Adeno-associated virus (AAV) gene therapy for neurological disease.

Authors:  Marc S Weinberg; R Jude Samulski; Thomas J McCown
Journal:  Neuropharmacology       Date:  2012-03-17       Impact factor: 5.250

10.  miRviewer: a multispecies microRNA homologous viewer.

Authors:  Adam Kiezun; Shay Artzi; Shira Modai; Naama Volk; Ofer Isakov; Noam Shomron
Journal:  BMC Res Notes       Date:  2012-02-13
View more
  96 in total

Review 1.  E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV Evolution.

Authors:  Dirk Grimm; Sergei Zolotukhin
Journal:  Mol Ther       Date:  2015-09-21       Impact factor: 11.454

2.  Intrathecal administration of AAV/GALC vectors in 10-11-day-old twitcher mice improves survival and is enhanced by bone marrow transplant.

Authors:  Subha Karumuthil-Melethil; Michael S Marshall; Clifford Heindel; Benas Jakubauskas; Ernesto R Bongarzone; Steven J Gray
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

3.  Redirecting N-acetylaspartate metabolism in the central nervous system normalizes myelination and rescues Canavan disease.

Authors:  Dominic J Gessler; Danning Li; Hongxia Xu; Qin Su; Julio Sanmiguel; Serafettin Tuncer; Constance Moore; Jean King; Reuben Matalon; Guangping Gao
Journal:  JCI Insight       Date:  2017-02-09

Review 4.  Viral vectors for therapy of neurologic diseases.

Authors:  Sourav R Choudhury; Eloise Hudry; Casey A Maguire; Miguel Sena-Esteves; Xandra O Breakefield; Paola Grandi
Journal:  Neuropharmacology       Date:  2016-02-21       Impact factor: 5.250

Review 5.  State-of-the-art human gene therapy: part I. Gene delivery technologies.

Authors:  Dan Wang; Guangping Gao
Journal:  Discov Med       Date:  2014 Jul-Aug       Impact factor: 2.970

Review 6.  Therapeutic potential of combined viral transduction and CRISPR/Cas9 gene editing in treating neurodegenerative diseases.

Authors:  Joshua Kuruvilla; Andrew Octavian Sasmita; Anna Pick Kiong Ling
Journal:  Neurol Sci       Date:  2018-08-03       Impact factor: 3.307

7.  Glymphatic fluid transport controls paravascular clearance of AAV vectors from the brain.

Authors:  Giridhar Murlidharan; Andrew Crowther; Rebecca A Reardon; Juan Song; Aravind Asokan
Journal:  JCI Insight       Date:  2016-09-08

8.  Optimization of Dexamethasone Administration for Maintaining Global Transduction Efficacy of Adeno-Associated Virus Serotype 9.

Authors:  Zheng Chai; Xintao Zhang; Amanda Lee Dobbins; Kelly Michelle Rigsbee; Bing Wang; Richard Jude Samulski; Chengwen Li
Journal:  Hum Gene Ther       Date:  2019-03-11       Impact factor: 5.695

9.  Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids.

Authors:  Michael J Castle; Heikki T Turunen; Luk H Vandenberghe; John H Wolfe
Journal:  Methods Mol Biol       Date:  2016

Review 10.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.